Clinical Trial Update: Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of teprotumumab in active thyroid eye disease completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy
• Thyroid Eye Disease
• Thyroid-associated Ophthalmopathy

Drugs mentioned

• Teprotumumab (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy | Phase 2 | Status: COMPLETED | Results posted: 2017-08-30